Ramiro Sanchez - 12 Aug 2025 Form 4 Insider Report for Alto Neuroscience, Inc. (ANRO)

Role
Director
Signature
/s/ Erin R. McQuade, Attorney-in-Fact
Issuer symbol
ANRO
Transactions as of
12 Aug 2025
Net transactions value
+$8,681
Form type
4
Filing time
14 Aug 2025, 17:22:27 UTC
Previous filing
18 Jun 2025
Next filing
06 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sanchez Ramiro Director C/O ALTO NEUROSCIENCE, INC., 650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW /s/ Erin R. McQuade, Attorney-in-Fact 14 Aug 2025 0001830326

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANRO Stock Option (right to buy) Award $0 +30,574 $0.000000 30,574 12 Aug 2025 Common Stock 30,574 $3.18 Direct F1, F2
transaction ANRO Stock Option (right to buy) Award $8,681 +3,928 $2.21 3,928 12 Aug 2025 Common Stock 3,928 $3.18 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option shall vest in 36 equal monthly installments commencing on September 12, 2025, subject to the Reporting Person's continuous service through each vesting date.
F2 The derivative securities were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.
F3 1,383 shares underlying the option shall vest on September 30, 2025, and 2,545 shares underlying the option shall vest on December 31, 2025, subject to the Reporting Person's continuous service through each such vesting date.
F4 This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $8,682.07.